REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata [Yahoo! Finance]
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Yahoo! Finance
Mean percent reduction in SALT scores at 36 weeks was 30% for both treatment arms versus 6% for placebo, achieving statistical significance (p Safety profile showed rezpegaldesleukin was well tolerated and was consistent with previously reported results Study results establish Phase 3 dose and support planned advancement to Phase 3 development in alopecia areata Conference call and webcast with management and alopecia areata experts today at 8:00 am ET SAN FRANCISCO Dec. 16, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin, a first-in-class IL-2 pathway agonist and regulatory T-cell (Treg) proliferator. The global Phase 2b study is being conducted in 92 patients with severe-to-very-severe alopecia areata. Patients were randomized (
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- iShares MSCI EAFE Growth ETF declares semi-annual distribution of $1.8057 [Seeking Alpha]Seeking Alpha
- iShares MSCI Indonesia ETF declares semi-annual distribution of $0.1615 [Seeking Alpha]Seeking Alpha
- iShares MSCI Emerging Markets Min Vol Factor ETF declares semi-annual distribution of $0.9748 [Seeking Alpha]Seeking Alpha
- iShares MSCI EAFE ETF declares semi-annual distribution of $1.7279 [Seeking Alpha]Seeking Alpha
- iShares MSCI EAFE Min Vol Factor ETF declares semi-annual distribution of $1.1733 [Seeking Alpha]Seeking Alpha
NKTR
Earnings
- 11/6/25 - Beat
NKTR
Sec Filings
- 12/16/25 - Form 8-K
- 11/25/25 - Form 4
- 11/25/25 - Form 4
- NKTR's page on the SEC website